| Animal models of Parkinson’s disease: bridging the gap between disease hallmarks and research questions A Dovonou, C Bolduc, V Soto Linan, C Gora, MR Peralta III, M Lévesque Translational neurodegeneration 12 (1), 36, 2023 | 16 | 2023 |
| Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2 G2019S model of Parkinson’s disease Z Gaertner, C Oram, A Schneeweis, E Schonfeld, C Bolduc, C Chen, ... bioRxiv, 2024 | 1 | 2024 |
| SLP-2 modulated expression rescues mitochondrial function in alpha-synuclein neuropathology models MPC Rueda, G Gentile, A Zanon, A Lavdas, C Bolduc, ML Picón, ... International Congress of Parkinson’s Disease and Movement Disorders, 2023 | | 2023 |
| Modulation of SLP-2 expression protects against alpha-synuclein neuropathology by mitigating mitochondrial dysfunction MP Castelo-Rueda, G Gentile, A Zanon, A Lavdas, C Bolduc, ML Picón, ... Cell Symposia: Multifaceted Mitochondria, 2022 | | 2022 |
| SLP-2 protects SNpc DA neurons against alpba-synuclein toxicity by rescuing mitochondrial functions in a mouse model of Parkinson's disease C Bolduc, ML Picon, S Laouafa, J Soliz, G Gentile, MP Castelo-Rueda, ... Keystone Symposia, 2022 | | 2022 |
| Validation du rôle neuroprotecteur de la protéine mitochondriale SLP-2 pour le traitement de la maladie de Parkinson C Bolduc | | 2022 |
| Validation of the Neuroprotective Potential of SLP-2 against alpha-synuclein neuropathology in a Mouse Model of Parkinson's Disease C Bolduc, ML Picon, S Laouafa, J Soliz, I Pichler, M Levesque MOVEMENT DISORDERS 36, S204-S204, 2021 | | 2021 |
